Czechs and Americans establish new medical research center

Representatives of the Organic and Biochemistry Institute of the Czech Academy of Sciences and the American biopharmaceutical company, Gilead Sciences, have signed an agreement on research cooperation. A new research center will be established in Prague, to which Gilead Sciences will contribute 1.1 million dollars (25 million Czech crowns) annually. The new research center will he headed by Czech scientist Antonin Holy and his team, who are also responsible for developing what is considered the best medicine for the treatment of AIDS. The agreement between the Czech scientific team and Gilead Sciences also includes financing of any approved drug patents.